COMMUNIQUÉS West-GlobeNewswire

Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index

21/06/2018 - 13:30

Marinus’ addition to the indexes will be effective June 22, 2018, after market close RADNOR, Pa., June 21, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a [...]

Syneos Health and Elligo Announce Strategic Collaboration to Advance Clinical Research for Real-World Patients

21/06/2018 - 13:30

AUSTIN, Texas and RALEIGH, N.C., June 21, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Elligo Health Research , the only platform that [...]

Moleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market

21/06/2018 - 13:30

HOUSTON, June 21, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, all of [...]

Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly

21/06/2018 - 13:30

SAN DIEGO, June 21, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine [...]

The Joint Corp. CFO to Depart in July

21/06/2018 - 13:05

SCOTTSDALE, Ariz., June 21, 2018 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ:JYNT), a national operator, manager and franchisor of chiropractic clinics, reported CFO John Meloun will resign effective July 20, 2018. [...]

Top-Five National Payer Issues Positive Coverage Decision for Myriad’s Prolaris® Test for Prostate Cancer

21/06/2018 - 13:05

Decision Follows Recently Updated Medical Guidelines for Prostate Cancer SALT LAKE CITY, June 21, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine [...]

Voyager Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for VY-AADC for the Treatment of Parkinson’s Disease

21/06/2018 - 13:03

CAMBRIDGE, Mass., June 21, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today [...]

Surface Oncology Recognized as one of the “Best Places to Work” by Boston Business Journal

21/06/2018 - 13:00

CAMBRIDGE, Mass., June 21, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today [...]

BeyondSpring Provides Operational Updates and First-Quarter 2018 Financial Results

21/06/2018 - 13:00

NEW YORK, June 21, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company) (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today [...]

The Hydropothecary Corporation Announces Graduation to the TSX, Shareholder Meeting for Rebranding to HEXO

21/06/2018 - 12:30

GATINEAU, Quebec, June 21, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (“THCX” or the “Company”) (TSX-V:THCX) announced today that it has received approval from the Toronto Stock Exchange (the “TSX”) to [...]

Inscription de la société Hydropothecary à la TSX et assemblée des actionnaires concernant la nouvelle marque HEXO

21/06/2018 - 12:30

GATINEAU, Québec, 21 juin 2018 (GLOBE NEWSWIRE) -- La société Hydropothecary (« THCX » ou la « Société ») (TSX-V:THCX) a annoncé aujourd’hui qu’elle a reçu l’approbation de la Bourse de Toronto (la « TSX ») lui [...]

Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting

21/06/2018 - 12:00

NEW YORK and MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic [...]

Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine

21/06/2018 - 12:00

SIOPEL 6 met primary endpoint (p=0.002) 48% reduction in the incidence of hearing loss No evidence of tumor protection RESEARCH TRIANGLE PARK, N.C., June 21, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: [...]

Wright Medical Group N.V. Announces Private Placement of $675 Million of 1.625% Cash Convertible Senior Notes Due 2023

21/06/2018 - 12:00

AMSTERDAM, The Netherlands, June 21, 2018 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) (the “Company”) today announced that it has entered into privately negotiated agreements among the Company, Wright [...]

PotNetwork Holdings, Inc.’s Diamond CBD Continues Surpassing $2 Million In Sales Per Month Practically Doubling Revenues Year Over Year

21/06/2018 - 12:00

Diamond CBD keeps breaking previous year’s records with May 2018 Sales FT LAUDERDALE, Fla., June 21, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--PotNetwork Holdings, Inc. (OTC Pink:POTN) is pleased to announce that its [...]

ViroGates’ initial public offering of new shares was 141% oversubscribed

21/06/2018 - 11:59

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. This announcement does not constitute a prospectus. No one [...]

Enrollment of first patient in Phase II clinical trial for Gaucher disease

21/06/2018 - 09:17

Orphazyme A/S Company announcement No. 08/2018 Company Registration No. 32266355 Copenhagen, June 21, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare [...]

Shire Announces FDA Approval for Label Expansion of CINRYZE® for Prevention of Attacks in Pediatric HAE

21/06/2018 - 08:00

Shire Announces FDA Approval for Label Expansion of CINRYZE ® (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients CINRYZE is the first and only therapy indicated in the [...]

ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC

21/06/2018 - 08:00

Press release Leuven, Belgium, 21 June 2018 - ThromboGenics NV (Euronext Brussels: THR), a biopharma company focused on developing novel treatments for back of the eye diseases with an innovative pipeline in diabetic [...]